(R)- N- (3- quinuclidinyl)- 7- oxo- dihydrothieno(3,2b)pyridine- 6- carboxamide hydrochloride

Subscribe to Selected New Research on (R)-N-(3-quinuclidinyl)-7-oxo-dihydrothieno(3,2b)pyridine-6-carboxamide hydrochloride

3 relevant articles (2 outcomes, 2 trials/studies) found for this Bio-Agent

Description: a 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in human

Also Known As:

DPP-733; MKC-733; Pumosetrag

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyridines: 26

(R)-N-(3-quinuclidinyl)-7-oxo-dihydrothieno(3,2b)pyridine-6-carboxamide hydrochloride: 3

Bridged-Ring Heterocyclic Compounds

Quinuclidines: 1

(R)-N-(3-quinuclidinyl)-7-oxo-dihydrothieno(3,2b)pyridine-6-carboxamide hydrochloride: 3

Experts

1.	Evangelista, Stefano: 1 article (05/2007)
2.	Sawada, M: 1 article (12/2005)
3.	Yokota, S: 1 article (12/2005)
4.	Fujita, T: 1 article (12/2005)
5.	Ohtani, Y: 1 article (12/2005)
6.	Majima, M: 1 article (12/2005)
7.	Kumagai, Y: 1 article (12/2005)

Related Diseases

1.	Constipation 12/01/2005 - "MKC-733 at the doses studied might be effective in increasing stool frequency and reduce gastrointestinal symptoms related to constipation" 05/01/2007 - "In September 2005, Dynogen commenced a phase II proof-of-concept trial of pumosetrag in IBS with constipation; positive results were reported in February 2007 and a phase IIb trial was to start in the fourth quarter of 2007" 12/01/2005 - "OBJECTIVE: The aim of this study was to explore the effects of MKC-733 on bowel motility and symptoms in a small group of subjects with constipation" 12/01/2005 - "Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study." 05/01/2007 - "Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD)" Get all the results and reference details, order at left...
2.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 05/01/2007 - "Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease." 05/01/2007 - "Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD)" Get all the results and reference details, order at left...
3.	Malaria 04/01/2006 - "This issue focuses on the following selection of drugs: ABT-510, adalimumab, alefacept, alemtuzumab, AMG-531, anakinra, armodafinil, asenapine maleate, atazanavir sulfate, atorvastatin; Bortezomib, bosentan; CEB-1555, cetuximab, ciclesonide, clodronate, CT-011; Darifenacin hydrobromide, desloratadine; E-7010, ecallantide, eculizumab, efalizumab, eltrombopag, erlotinib hydrochloride, eslicarbazepine acetate, eszopiclone, ezetimibe; Febuxostat, fosamprenavir calcium, fulvestrant; Gefitinib, genistein; Haemophilus influenzae B vaccine, human papillomavirus vaccine; Imatinib mesylate, insulin glargine; Lenalidomide, liposomal cisplatin; MAb G250, mapatumumab, midostaurin, MP4, mycophenolic acid sodium salt; Natalizumab, neridronic acid, NSC-330507; Oblimersen sodium, ofatumumab, omalizumab, oral insulin, oregovomab; Paliperidone, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pegylated arginine deiminase 20000, pemetrexed disodium, pimecrolimus, pitavastatin, pneumococcal 7-valent conjugate vaccine, prasterone, pregabalin, pumosetrag hydrochloride; Recombinant malaria vaccine, retigabine, rivaroxaban, Ro-26-9228, romidepsin, rosuvastatin calcium, rotavirus vaccine; SGN-30, sitaxsentan sodium, solifenacin succinate, sorafenib, sunitinib malate; Tadalafil, tegaserod maleate, temsirolimus, TER-199, tifacogin, tiludronic acid, tiotropium bromide; Vildagliptin, VNP-40101M, vorinostat; YM-150, yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zoledronic acid monohydrate." Get all the results and reference details, order at left...
4.	Gastroesophageal Reflux (GERD) 05/01/2007 - "Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease." 05/01/2007 - "Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD)" Get all the results and reference details, order at left...
4 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
3.	Genistein
4.	Succinic Acid (Succinate)
5.	Yttrium
6.	Sodium
7.	Ribavirin (Virazole)
8.	Mycophenolic Acid
9.	Insulin (Novolin)
10.	Clodronic Acid (Clodronate)
80 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>